TY - JOUR
AU1 - Steinberg, Jonathan S.
AU2 - Garikipati, Naga Vamsi
AB - Editorial Comment Received: August 6, 2010 Cardiology 2010;117:11–13 Accepted: August 6, 2010 DOI: 10.1159/000320069 Published online: September 29, 2010 Reducing the Risk of Recurrences after Pulmonary Vein Isolation: What Is the Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers? Jonathan S. Steinberg Naga Vamsi Garikipati Al-Sabah Arrhythmia Institute, Division of Cardiology, St. Luke’s and Roosevelt Hospitals, Columbia University College of Physicians and Surgeons, New York, N.Y. , USA Catheter ablation, primarily using pulmonary vein predict long-term clinical failure [1] . Current guidelines isolation (PVI), is an important treatment modality for recommend deferring a repeat ablation procedure for at symptomatic drug-refractory atrial fibrillation (AF) and least 3 months [4] . has been shown to be superior to medical treatment in Late recurrence of AF (LRAF) is defined as a recur- randomized controlled clinical trials. The unpredictable rence of AF after 3 months and within a year and occurs recurrence of AF after ablation has been proven to be a in up to 38% of patients [5] . The reported wide variation not infrequent event and has serious therapeutic implica- in recurrence rates can be attributed to differences in pa- tions for symptom control as well as anticoagulation for tient population, ablation techniques, definition 
TI - Reducing the Risk of Recurrences after Pulmonary Vein Isolation: What Is the Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers?
JF - Cardiology
DO - 10.1159/000320069
DA - 2010-01-01
UR - https://www.deepdyve.com/lp/karger/reducing-the-risk-of-recurrences-after-pulmonary-vein-isolation-what-0ch3l7EcWF
SP - 11
EP - 13
VL - 117
IS - 1
DP - DeepDyve
ER -